
Halidou Tinto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2620584/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Boosting the impact of seasonal malaria chemoprevention (SMC) through simultaneous screening and treatment of household members of children receiving SMC in Burkina Faso: a protocol for a randomized open label trial. Archives of Public Health, 2022, 80, 41.	2.4	1
2	Nasopharyngeal colonisation dynamics of bacterial pathogens in patients with fever in rural Burkina Faso: an observational study. BMC Infectious Diseases, 2022, 22, 15.	2.9	5
3	Impact of seasonal RTS,S/AS01E vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali. Malaria Journal, 2022, 21, 59.	2.3	1
4	Genetic associations with carotid intima-media thickness link to atherosclerosis with sex-specific effects in sub-Saharan Africans. Nature Communications, 2022, 13, 855.	12.8	10
5	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5.5	9
6	Low birth weight and its associated risk factors in a rural health district of Burkina Faso: a cross sectional study. BMC Pregnancy and Childbirth, 2022, 22, 228.	2.4	5
7	Age-modified factors associated with placental malaria in rural Burkina Faso. BMC Pregnancy and Childbirth, 2022, 22, 248.	2.4	3
8	Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso. International Journal of Infectious Diseases, 2022, 118, 224-229.	3.3	3
9	The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine. Clinical Infectious Diseases, 2022, 75, 613-622.	5.8	5
10	Use of WATCH antibiotics prior to presentation to the hospital in rural Burkina Faso. Antimicrobial Resistance and Infection Control, 2022, 11, 59.	4.1	9
11	Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection. JCI Insight, 2022, 7, .	5.0	6
12	Changing Dietary Habits: The Impact of Urbanization and Rising Socio-Economic Status in Families from Burkina Faso in Sub-Saharan Africa. Nutrients, 2022, 14, 1782.	4.1	16
13	Meta-analysis of sub-Saharan African studies provides insights into genetic architecture of lipid traits. Nature Communications, 2022, 13, 2578.	12.8	18
14	Risk of malaria in young children after periconceptional iron supplementation. Maternal and Child Nutrition, 2021, 17, e13106.	3.0	7
15	The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali. Clinical Infectious Diseases, 2021, 73. e2379-e2386.	5.8	10
16	Pathogens associated with acute diarrhea, and comorbidity with malaria among children under five years old in rural Burkina Faso. Pan African Medical Journal, 2021, 38, 259.	0.8	2
17	Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. Malaria Journal, 2021, 20, 48.	2.3	43
18	Plasmodium falciparum gametocyte carriage in symptomatic patients shows significant association with genetically diverse infections, anaemia, and asexual stage density. Malaria Journal, 2021, 20, 31.	2.3	7

#	Article	IF	CITATIONS
19	Genetic variation in the immune system and malaria susceptibility in infants: a nested case–control study in Nanoro, Burkina Faso. Malaria Journal, 2021, 20, 94.	2.3	7
20	Adiposity Phenotypes and Subclinical Atherosclerosis in Adults from Sub–Saharan Africa: An H3Africa AWl–Gen Study. Global Heart, 2021, 16, 19.	2.3	2
21	Infection Manager System (IMS) as a new hemocytometry-based bacteremia detection tool: A diagnostic accuracy study in a malaria-endemic area of Burkina Faso. PLoS Neglected Tropical Diseases, 2021, 15, e0009187.	3.0	4
22	Antibiotic Susceptibility of Staphylococcus aureus and Streptococcus pneumoniae Isolates from the Nasopharynx of Febrile Children under 5 Years in Nanoro, Burkina Faso. Antibiotics, 2021, 10, 444.	3.7	6
23	A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria. Malaria Journal, 2021, 20, 222.	2.3	29
24	Asymptomatic malaria and anaemia among pregnant women during high and low malaria transmission seasons in Burkina Faso: household-based cross-sectional surveys in Burkina Faso, 2013 and 2017. Malaria Journal, 2021, 20, 211.	2.3	11
25	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet, The, 2021, 397, 1809-1818.	13.7	253
26	Assessment of a combined strategy of seasonal malaria chemoprevention and supplementation with vitamin A, zinc and Plumpy'Doz™ to prevent malaria and malnutrition in children under 5 years old in Burkina Faso: a randomized open-label trial (SMC-NUT). Trials, 2021, 22, 360.	1.6	5
27	Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria. Malaria Journal, 2021, 20, 274.	2.3	5
28	Altered Ex-Vivo Cytokine Responses in Children With Asymptomatic Plasmodium falciparum Infection in Burkina Faso: An Additional Argument to Treat Asymptomatic Malaria?. Frontiers in Immunology, 2021, 12, 614817.	4.8	3
29	Antibiotic susceptibility profile of bacterial isolates from febrile children under 5 years of age in Nanoro, Burkina Faso. Tropical Medicine and International Health, 2021, 26, 1220-1230.	2.3	6
30	Effect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness. Malaria Journal, 2021, 20, 326.	2.3	1
31	Patterns of child mortality in rural area of Burkina Faso: evidence from the Nanoro health and demographic surveillance system (HDSS). BMC Public Health, 2021, 21, 1425.	2.9	3
32	Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. New England Journal of Medicine, 2021, 385, 1005-1017.	27.0	114
33	Seasonal patterns of malaria, genital infection, nutritional and iron status in non-pregnant and pregnant adolescents in Burkina Faso: a secondary analysis of trial data. BMC Public Health, 2021, 21, 1764.	2.9	7
34	Associations between dental problems and underweight status among rural women in Burkina Faso: results from the first WHO Stepwise Approach to Surveillance (STEPS) survey. Public Health Nutrition, 2021, , 1-11.	2.2	1
35	Association of malaria and curable sexually transmitted infections with pregnancy outcomes in rural Burkina Faso. BMC Pregnancy and Childbirth, 2021, 21, 722.	2.4	4
36	The effect of malaria on haemoglobin concentrations: a nationally representative household fixed-effects study of 17,599 children under 5Âyears of age in Burkina Faso. Malaria Journal, 2021, 20, 416.	2.3	12

#	Article	lF	CITATIONS
37	Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus. PLoS ONE, 2021, 16, e0257190.	2.5	4
38	Magnitude of low birthweight in malaria endemic settings of Nanoro, rural Burkina Faso: a secondary data analysis. Scientific Reports, 2021, 11, 21332.	3.3	2
39	Malaria and curable sexually transmitted and reproductive tract coinfection among pregnant women in rural Burkina Faso. Tropical Medicine and Health, 2021, 49, 90.	2.8	1
40	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1187-1198.	2.0	8
41	Malaria early in the first pregnancy: Potential impact of iron status. Clinical Nutrition, 2020, 39, 204-214.	5.0	15
42	In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal, 2020, 19, 8.	2.3	17
43	Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Vaccine, 2020, 38, 897-906.	3.8	12
44	â€~Men are not playing their roles', maternal and child nutrition in Nanoro, Burkina Faso. Public Health Nutrition, 2020, 24, 1-11.	2.2	9
45	Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso. Malaria Journal, 2020, 19, 399.	2.3	1
46	Fetal biometry assessment with Intergrowth 21st's and Salomon's equations in rural Burkina Faso. BMC Pregnancy and Childbirth, 2020, 20, 492.	2.4	5
47	Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali. PLoS Medicine, 2020, 17, e1003214.	8.4	18
48	Determinants of Plasmodium falciparum multiplicity of infection and genetic diversity in Burkina Faso. Parasites and Vectors, 2020, 13, 427.	2.5	35
49	A microplanning model to improve door-to-door health service delivery: the case of Seasonal Malaria Chemoprevention in Sub-Saharan African villages. BMC Health Services Research, 2020, 20, 1128.	2.2	2
50	Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
51	Severe-malaria infection and its outcomes among pregnant women in Burkina Faso health-districts: Hierarchical Bayesian space-time models applied to routinely-collected data from 2013 to 2018. Spatial and Spatio-temporal Epidemiology, 2020, 33, 100333.	1.7	7
52	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 943-952.	9.1	25
53	Iron Status of Burkinabé Adolescent Girls Predicts Malaria Risk in the Following Rainy Season. Nutrients, 2020, 12, 1446.	4.1	5
54	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2020, 18, 138.	5.5	16

#	Article	IF	CITATIONS
55	Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children. Tropical Medicine and International Health, 2020, 25, 740-750.	2.3	4
56	The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine, 2020, 18, 47.	5.5	22
57	Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01 _E malaria vaccine in African children: a randomized trial. Human Vaccines and Immunotherapeutics, 2020, 16, 1464-1470.	3.3	5
58	The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey. BMC Infectious Diseases, 2020, 20, 46.	2.9	15
59	Smokeless tobacco use: its prevalence and relationships with dental symptoms, nutritional status and blood pressure among rural women in Burkina Faso. BMC Public Health, 2020, 20, 579.	2.9	12
60	<p>Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso</p> . Drug Design, Development and Therapy, 2020, Volume 14, 1507-1521.	4.3	8
61	First trimester use of artemisinin-based combination therapy and the risk of low birth weight and small for gestational age. Malaria Journal, 2020, 19, 144.	2.3	8
62	Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01 _E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention. BMJ Open, 2020, 10, e035433.	1.9	15
63	Red blood cell homeostasis in children and adults with and without asymptomatic malaria infection in Burkina Faso. PLoS ONE, 2020, 15, e0242507.	2.5	6
64	Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin. American Journal of Tropical Medicine and Hygiene, 2020, 103, 679-683.	1.4	2
65	Drug safety in Burkina Faso. , 2020, , 569-584.		1
66	Malaria and curable sexually transmitted infections in pregnant women: A two-years observational study in rural Burkina Faso. PLoS ONE, 2020, 15, e0242368.	2.5	5
67	Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia,) Tj ETQq1 1 586-596.	0.784314 rgB	BT /Overlock
68	Classical Cardiovascular Risk Factors and HIV are Associated With Carotid Intimaâ€Media Thickness in Adults From Subâ€Saharan Africa: Findings From H3Africa AWIâ€Gen Study. Journal of the American Heart Association, 2019, 8, e011506.	3.7	20
69	Long-term incidence of severe malaria following RTS,S/ASO1 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2019, 19, 821-832.	9.1	45
70	Supporting evidence for a human reservoir of invasive non-Typhoidal Salmonella from household samples in Burkina Faso. PLoS Neglected Tropical Diseases, 2019, 13, e0007782.	3.0	36
71	Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae. Tropical Medicine and International Health, 2019, 24, 1442-1454.	2.3	7
72	Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. New England Journal of Medicine, 2019, 380, 2197-2206.	27.0	54

#	Article	IF	CITATIONS
73	The effect of malaria rapid diagnostic tests results on antimicrobial prescription practices of health care workers in Burkina Faso. Annals of Clinical Microbiology and Antimicrobials, 2019, 18, 5.	3.8	19
74	The assessment of gestational age: a comparison of different methods from a malaria pregnancy cohort in sub-Saharan Africa. BMC Pregnancy and Childbirth, 2019, 19, 12.	2.4	21
75	<p>High adherence level to artemisinin-based combination therapies in rural settlement 11 years after their introduction in the health system, Nanoro, Burkina Faso</p> . Patient Preference and Adherence, 2019, Volume 13, 371-380.	1.8	4
76	The XN-30 hematology analyzer for rapid sensitive detection of malaria: a diagnostic accuracy study. BMC Medicine, 2019, 17, 103.	5.5	24
77	Excess risk of preterm birth with periconceptional iron supplementation in a malaria endemic area: analysis of secondary data on birth outcomes in a double blind randomized controlled safety trial in Burkina Faso. Malaria Journal, 2019, 18, 161.	2.3	24
78	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nature Communications, 2019, 10, 2174.	12.8	123
79	Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2019, 15, 2386-2398.	3.3	48
80	Socioeconomic and environmental factors associated with malaria hotspots in the Nanoro demographic surveillance area, Burkina Faso. BMC Public Health, 2019, 19, 249.	2.9	32
81	Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study. Malaria Journal, 2019, 18, 105.	2.3	12
82	Algorithms for sequential interpretation of a malaria rapid diagnostic test detecting two different targets of Plasmodium species to improve diagnostic accuracy in a rural setting (Nanoro, Burkina) Tj ETQq0 0 0 i	rgBZ.\$Over	lock 10 Tf 50
83	Prevalence and factors associated with overweight and obesity among rural and urban women in Burkina Faso. Pan African Medical Journal, 2019, 34, 199.	0.8	9
84	Testing an infection model to explain excess risk of preterm birth with long-term iron supplementation in a malaria endemic area. Malaria Journal, 2019, 18, 374.	2.3	4
85	Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. Scientific Reports, 2019, 9, 127.	3.3	39
86	Novel and Known Gene-Smoking Interactions With cIMT Identified as Potential Drivers for Atherosclerosis Risk in West-African Populations of the AWI-Gen Study. Frontiers in Genetics, 2019, 10, 1354.	2.3	10
87	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 2019, 4, 45.	1.8	1
88	Strength in Numbers: The WWARN Case Study of Purpose-Driven Data Sharing. American Journal of Tropical Medicine and Hygiene, 2019, 100, 13-15.	1.4	10
89	Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. Human Vaccines and Immunotherapeutics, 2018, 14, 1489-1500.	3.3	14
90	Additional Screening and Treatment of Malaria During Pregnancy Provides Further Protection Against Malaria and Nonmalarial Fevers During the First Year of Life. Journal of Infectious Diseases, 2018, 217, 1967-1976.	4.0	8

#	Article	IF	CITATIONS
91	Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections. Nature Communications, 2018, 9, 1381.	12.8	27
92	High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies. BMC Public Health, 2018, 18, 551.	2.9	26
93	Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study. Malaria Journal, 2018, 17, 163.	2.3	21
94	Community approval required for periconceptional adolescent adherence to weekly iron and/or folic acid supplementation: a qualitative study in rural Burkina Faso. Reproductive Health, 2018, 15, 48.	3.1	9
95	Regional and sex-specific variation in BMI distribution in four sub-Saharan African countries: The H3Africa AWI-Gen study. Global Health Action, 2018, 11, 1556561.	1.9	37
96	Can clinical signs or symptoms combined with basic hematology data be used to predict the presence of bacterial infections in febrile children under - 5 years?. BMC Pediatrics, 2018, 18, 370.	1.7	1
97	Fear and rumours regarding placental biopsies in a malaria-in-pregnancy trial in Benin. Malaria Journal, 2018, 17, 425.	2.3	18
98	Spatial distribution and determinants of asymptomatic malaria risk among children under 5Âyears in 24 districts in Burkina Faso. Malaria Journal, 2018, 17, 460.	2.3	21
99	Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study. Global Health Action, 2018, 11, 1507133.	1.9	82
100	Modulation of innate immune responses at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC Medicine, 2018, 16, 198.	5.5	24
101	Gender differences in sociodemographic and behavioural factors associated with BMI in an adult population in rural Burkina Faso – an AWI-Gen sub-study. Clobal Health Action, 2018, 11, 1527557.	1.9	8
102	Implementation of a malaria rapid diagnostic test in a rural setting of Nanoro, Burkina Faso: from expectation to reality. Malaria Journal, 2018, 17, 316.	2.3	9
103	In Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-4.	1.2	9
104	Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study. Drugs - Real World Outcomes, 2018, 5, 193-206.	1.6	12
105	Treatable causes of fever among children under five years in a seasonal malaria transmission area in Burkina Faso. Infectious Diseases of Poverty, 2018, 7, 60.	3.7	29
106	Effects of Weekly Iron and Folic Acid Supplements on Malaria Risk in Nulliparous Women in Burkina Faso: A Periconceptional, Double-Blind, Randomized Controlled Noninferiority Trial. Journal of Infectious Diseases, 2018, 218, 1099-1109.	4.0	18
107	Diagnosing congenital malaria in a high-transmission setting: clinical relevance and usefulness of P. falciparum HRP2-based testing. Scientific Reports, 2017, 7, 2080.	3.3	24
108	Presence of quintuple dhfr N51, C59, S108 – dhps A437, K540 mutations in Plasmodium falciparum isolates from pregnant women and the general population in Nanoro, Burkina Faso. Molecular and Biochemical Parasitology, 2017, 217, 13-15.	1.1	8

#	Article	IF	CITATIONS
109	Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso. Malaria Journal, 2017, 16, 38.	2.3	21
110	Increase in the prevalence of mutations associated with sulfadoxine–pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso. Malaria Journal, 2017, 16, 179.	2.3	19
111	Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients. Malaria Journal, 2017, 16, 188.	2.3	8
112	Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malaria Journal, 2017, 16, 182.	2.3	31
113	Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. The Lancet Global Health. 2017. 5. e60-e68.	6.3	15
114	Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Global Health, 2017, 2, e000371.	4.7	23
115	Population-based incidence, seasonality and serotype distribution of invasive salmonellosis among children in Nanoro, rural Burkina Faso. PLoS ONE, 2017, 12, e0178577.	2.5	31
116	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. PLoS Medicine, 2017, 14, e1002373.	8.4	46
117	A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Medicine, 2017, 15, 181.	5.5	49
118	Effects of long-term weekly iron and folic acid supplementation on lower genital tract infection – a double blind, randomised controlled trial in Burkina Faso. BMC Medicine, 2017, 15, 206.	5.5	19
119	Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries. Malaria Journal, 2017, 16, 433.	2.3	17
120	Accuracy of a Plasmodium falciparum specific histidine-rich protein 2 rapid diagnostic test in the context of the presence of non-malaria fevers, prior anti-malarial use and seasonal malaria transmission. Malaria Journal, 2017, 16, 294.	2.3	31
121	Regional and Sex Differences in the Prevalence and Awareness of Hypertension: An H3Africa AWI-Gen Study Across 6 Sites in Sub-Saharan Africa. Global Heart, 2017, 12, 81.	2.3	105
122	First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. PLoS Medicine, 2017, 14, e1002290.	8.4	66
123	Evaluation of Malaria Screening during Pregnancy with Rapid Diagnostic Tests Performed by Community Health Workers in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1190-1197.	1.4	18
124	Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso. Annals of Parasitology, 2017, 63, 127-131.	0.1	1
125	Severe anaemia associated with Plasmodium falciparum infection in children: consequences for additional blood sampling for research. Malaria Journal, 2016, 15, 304.	2.3	7
126	Diagnosis of Bacterial Bloodstream Infections: A 16S Metagenomics Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004470.	3.0	49

#	Article	IF	CITATIONS
127	Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms. PLoS ONE, 2016, 11, e0164851.	2.5	13
128	Phylogenomic Analysis Reveals an Asian Origin for African Burkholderia pseudomallei and Further Supports Melioidosis Endemicity in Africa. MSphere, 2016, 1, .	2.9	57
129	It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials. BMJ Global Health, 2016, 1, e000122.	4.7	16
130	Using health and demographic surveillance systems for teratovigilance in Africa. The Lancet Global Health, 2016, 4, e906.	6.3	2
131	Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. BMJ Open, 2016, 6, e012697.	1.9	7
132	Aetiologies of nonâ€malaria febrile episodes in children under 5 years in subâ€Saharan Africa. Tropical Medicine and International Health, 2016, 21, 943-955.	2.3	17
133	Perspectives on the design and methodology of periconceptional nutrient supplementation trials. Trials, 2016, 17, 58.	1.6	4
134	Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine, 2016, 374, 913-927.	27.0	83
135	Towards Improving Point-of-Care Diagnosis of Non-malaria Febrile Illness: A Metabolomics Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004480.	3.0	16
136	Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLoS ONE, 2016, 11, e0151565.	2.5	37
137	Four artemisinin-based treatments in African pregnant women with malaria. Malawi Medical Journal, 2016, 28, 139-149.	0.6	9
138	Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso. Annals of Parasitology, 2016, 62, 17-24.	0.1	2
139	Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. Reproductive Health, 2015, 12, 112.	3.1	20
140	Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal, 2015, 14, 251.	2.3	3
141	Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria Journal, 2015, 14, 325.	2.3	22
142	Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan African Medical Journal, 2015, 21, 101.	0.8	11
143	Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. PLoS ONE, 2015, 10, e0137440.	2.5	17
144	Increased systemic exposures of artemether and dihydroartemisinin in infants under 5Åkg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®). Malaria Journal, 2015, 14, 157.	2.3	8

#	Article	IF	CITATIONS
145	Participation in medical research as a resourceâ€seeking strategy in socioâ€economically vulnerable communities: call for research and action. Tropical Medicine and International Health, 2015, 20, 63-66.	2.3	18
146	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	5.5	37
147	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. New England Journal of Medicine, 2015, 373, 2025-2037.	27.0	332
148	Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infectious Diseases, The, 2015, 15, 1409-1419.	9.1	67
149	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1450-1458.	9.1	262
150	<i>In Vivo</i> Selection of Plasmodium falciparum <i>Pfcrt</i> and <i>Pfmdr1</i> Variants by Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2015, 59, 734-737.	3.2	36
151	Paediatric Pharmacovigilance: Use of Pharmacovigilance Data Mining Algorithms for Signal Detection in a Safety Dataset of a Paediatric Clinical Study Conducted in Seven African Countries. PLoS ONE, 2014, 9, e96388.	2.5	6
152	Paracheck® rapid diagnostic test for detecting malaria infection in under five children: a population-based survey in Burkina Faso. Malaria Journal, 2014, 13, 101.	2.3	12
153	Malaria prevention measures in Burkina Faso: distribution and households expenditures. International Journal for Equity in Health, 2014, 13, 108.	3.5	6
154	Accuracy of Pf HRP2 versus Pf-pLDH antigen detection by malaria rapid diagnostic tests in hospitalized children in a seasonal hyperendemic malaria transmission area in Burkina Faso. Malaria Journal, 2014, 13, 20.	2.3	35
155	Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. Journal of Antimicrobial Chemotherapy, 2014, 69, 2499-2507.	3.0	31
156	Effectiveness of artesunate–amodiaquine <i>vs</i> . artemether–lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in Nanoro, Burkina Faso: a nonâ€inferiority randomised trial. Tropical Medicine and International Health, 2014, 19, 469-475.	2.3	24
157	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
158	Community-based scheduled screening and treatment of malaria in pregnancy for improved maternal and infant health in The Gambia, Burkina Faso and Benin: study protocol for a randomized controlled trial. Trials, 2014, 15, 340.	1.6	21
159	The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malaria Journal, 2014, 13, 113.	2.3	19
160	Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal, 2014, 13, 207.	2.3	22
161	Frequency of Severe Malaria and Invasive Bacterial Infections among Children Admitted to a Rural Hospital in Burkina Faso. PLoS ONE, 2014, 9, e89103.	2.5	62
162	Artemisinin resistance in rodent malaria - mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking. Malaria Journal, 2013, 12, 118.	2.3	55

#	Article	IF	CITATIONS
163	Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial. Trials, 2013, 14, 307.	1.6	9
164	Clinical signs and symptoms cannot reliably predict Plasmodium falciparum malaria infection in pregnant women living in an area of high seasonal transmission. Malaria Journal, 2013, 12, 464.	2.3	23
165	Malaria mortality estimates: need for agreeable approach. Tropical Medicine and International Health, 2013, 18, 219-221.	2.3	10
166	Challenges of nonâ€commercial multicentre <scp>N</scp> orthâ€ <scp>S</scp> outh collaborative clinical trials. Tropical Medicine and International Health, 2013, 18, 237-241.	2.3	12
167	Good Clinical Practice in Resource-Limited Settings: Translating Theory into Practice. American Journal of Tropical Medicine and Hygiene, 2013, 88, 608-613.	1.4	14
168	Should Malaria Treatment Be Guided by a Point of Care Rapid Test? A Threshold Approach to Malaria Management in Rural Burkina Faso. PLoS ONE, 2013, 8, e58019.	2.5	6
169	Could the Decision of Trial Participation Precede the Informed Consent Process? Evidence From Burkina Faso. PLoS ONE, 2013, 8, e80800.	2.5	35
170	Profile: Nanoro Health and Demographic Surveillance System. International Journal of Epidemiology, 2012, 41, 1293-1301.	1.9	79
171	Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria. New England Journal of Medicine, 2012, 366, 1298-1309.	27.0	68
172	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
173	Evaluation of Antigen Detection Tests, Microscopy, and Polymerase Chain Reaction for Diagnosis of Malaria in Peripheral Blood in Asymptomatic Pregnant Women in Nanoro, Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2012, 87, 251-256.	1.4	32
174	An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal, 2012, 11, 71.	2.3	74
175	Antigen persistence of rapid diagnostic tests in pregnant women in Nanoro, Burkina Faso, and the implications for the diagnosis of malaria in pregnancy. Tropical Medicine and International Health, 2012, 17, 550-557.	2.3	47
176	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 2011, 365, 1863-1875.	27.0	773
177	Strict adherence to malaria rapid test results might lead to a neglect of other dangerous diseases: a cost benefit analysis from Burkina Faso. Malaria Journal, 2011, 10, 226.	2.3	24
178	Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes. Malaria Journal, 2010, 9, 324.	2.3	18
179	Accuracy of a rapid diagnostic test on the diagnosis of malaria infection and of malaria - attributable fever during low and high transmission season in Burkina Faso. Malaria Journal, 2010, 9, 192.	2.3	70
180	Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial. PLoS ONE, 2009, 4, e7871.	2.5	125

#	Article	IF	CITATIONS
181	Performance of OptiMAL-IT [®] compared to microscopy, for malaria detection in Burkina Faso. Tropical Medicine and International Health, 2009, 14, 338-340.	2.3	20
182	Rapid malaria diagnostic tests <i>vs.</i> clinical management of malaria in rural Burkina Faso: safety and effect on clinical decisions. A randomized trial. Tropical Medicine and International Health, 2009, 14, 491-498.	2.3	103
183	Chloroquineâ€resistance molecular markers (<i>Pfcrt</i> T76 and <i>Pfmdrâ€l </i> Y86) and amodiaquine resistance in Burkina Faso. Tropical Medicine and International Health, 2008, 13, 238-240.	2.3	39
184	Failure to detect Plasmodium vivax in West and Central Africa by PCR species typing. Malaria Journal, 2008, 7, 174.	2.3	75
185	Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet, The, 2007, 369, 491-498.	13.7	108
186	SULFADOXINE–PYRIMETHAMINE EFFICACY AND SELECTION OF PLASMODIUM FALCIPARUM DHFR MUTATIONS IN BURKINA FASO BEFORE ITS INTRODUCTION AS INTERMITTENT PREVENTIVE TREATMENT FOR PREGNANT WOMEN. American Journal of Tropical Medicine and Hygiene, 2007, 76, 608-613.	3 1.4	30
187	Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal of Tropical Medicine and Hygiene, 2007, 76, 608-13.	1.4	18
188	In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 509-514.	1.8	38
189	USEFULNESS OF THE PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANCE TRANSPORTER T76 GENOTYPE FAILURE INDEX FOR THE ESTIMATION OF IN VIVO CHLOROQUINE RESISTANCE IN BURKINA FASO. American Journal of Tropical Medicine and Hygiene, 2005, 73, 171-173.	1.4	15
190	Usefulness of the Plasmodium falciparum chloroquine resistance transporter T76 genotype failure index for the estimation of in vivo chloroquine resistance in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2005, 73, 171-3.	1.4	7
191	Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Infection, Genetics and Evolution, 2003, 3, 287-292.	2.3	29
192	Antiplasmodial Compounds fromCochlospermumtinctorium. Journal of Natural Products, 2002, 65, 1325-1327.	3.0	34
193	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 0, 4, 45.	1.8	0